Lansoprazole may stop tuberculosis, says study

20 November 2017
tuberculosis_large

The gastric acid suppressant lansoprazole could work against the bacteria that cause tuberculosis (TB), according to new research from University College London (UCL) and the London School of Hygiene and Tropical Medicine.

The study, published today in PLOS Medicine, found that people who used lansoprazole, as opposed to similar drugs omeprazole or pantoprazole, were a third less likely to develop TB.

Lansoprazole, the active ingredient of off-patent Takepron from Japan’s Takeda (TYO: 4502),  is a cheap and widely-used drug, and treats conditions including heartburn, gastritis and ulcers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical